Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21016902 | 0.78 | PIK3CA (0.32) | — | |
| SCHEMBL12049968 | 0.78 | HRH3 (0.38) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL12841653 | 0.76 | — | — | |
| SCHEMBL7698108 | 0.76 | CTSV (0.35) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL12030698 | 0.76 | HRH3 (0.42) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL22388258 | 0.76 | — | — | |
| SCHEMBL23806786 | 0.74 | HRH3 (0.40) | CARM1PRMT6 | |
| SCHEMBL19364761 | 0.74 | CHRM2 (0.31) | — | |
| SCHEMBL18704890 | 0.73 | HTT (0.36) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL19939281 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073538-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073538-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | CTSV 129/4885CTSL 534/4885CTSB 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.